175 related articles for article (PubMed ID: 33028593)
1. Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence.
Xie H; Mahoney DW; Foote PH; Burger KN; Doering KA; Taylor WR; Then SS; Cao X; McGlinch M; Berger CK; Wu TT; Hubbard JM; Allawi HT; Kaiser MW; Lidgard GP; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 Jan; 27(1):141-149. PubMed ID: 33028593
[TBL] [Abstract][Full Text] [Related]
2. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
3. Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma.
Qin Y; Wu CW; Taylor WR; Sawas T; Burger KN; Mahoney DW; Sun Z; Yab TC; Lidgard GP; Allawi HT; Buttar NS; Smyrk TC; Iyer PG; Katzka DA; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2019 Dec; 25(24):7396-7404. PubMed ID: 31527170
[TBL] [Abstract][Full Text] [Related]
4. Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Marinelli LM; Kisiel JB; Slettedahl SW; Mahoney DW; Lemens MA; Shridhar V; Taylor WR; Staub JK; Cao X; Foote PH; Burger KN; Berger CK; O'Connell MC; Doering KA; Giakoumopoulos M; Berg H; Volkmann C; Solsrud A; Allawi HT; Kaiser M; Vaccaro AM; Albright Crawford C; Moehlenkamp C; Shea G; Deist MS; Schoolmeester JK; Kerr SE; Sherman ME; Bakkum-Gamez JN
Gynecol Oncol; 2022 Jun; 165(3):568-576. PubMed ID: 35370009
[TBL] [Abstract][Full Text] [Related]
5. Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma.
Anderson BW; Suh YS; Choi B; Lee HJ; Yab TC; Taylor WR; Dukek BA; Berger CK; Cao X; Foote PH; Devens ME; Boardman LA; Kisiel JB; Mahoney DW; Slettedahl SW; Allawi HT; Lidgard GP; Smyrk TC; Yang HK; Ahlquist DA
Clin Cancer Res; 2018 Nov; 24(22):5724-5734. PubMed ID: 29844130
[No Abstract] [Full Text] [Related]
6. Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies.
Zhu M; Taylor WR; Mahoney DW; Then SS; Berger CK; Burger KN; Gonser AM; Doering KA; Xie H; Foote PH; Kaiser MW; Allawi HT; Hubbard JM; Kisiel JB
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136324
[TBL] [Abstract][Full Text] [Related]
7. A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer.
Young GP; Pedersen SK; Mansfield S; Murray DH; Baker RT; Rabbitt P; Byrne S; Bambacas L; Hollington P; Symonds EL
Cancer Med; 2016 Oct; 5(10):2763-2772. PubMed ID: 27726312
[TBL] [Abstract][Full Text] [Related]
8. Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing.
Majumder S; Taylor WR; Yab TC; Berger CK; Dukek BA; Cao X; Foote PH; Wu CW; Mahoney DW; Aslanian HR; Fernández-Del Castillo C; Doyle LA; Farrell JJ; Fisher WE; Lee LS; Lee YN; Park W; Rodrigues C; Gould Rothberg BE; Salem RR; Simeone DM; Urs S; Van Buren G; Smyrk TC; Allawi HT; Lidgard GP; Raimondo M; Chari ST; Kendrick ML; Kisiel JB; Topazian MD; Ahlquist DA
Am J Gastroenterol; 2019 Sep; 114(9):1539-1549. PubMed ID: 31306149
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.
Kisiel JB; Dukek BA; V S R Kanipakam R; Ghoz HM; Yab TC; Berger CK; Taylor WR; Foote PH; Giama NH; Onyirioha K; Abdallah MA; Burger KN; Slettedahl SW; Mahoney DW; Smyrk TC; Lewis JT; Giakoumopoulos M; Allawi HT; Lidgard GP; Roberts LR; Ahlquist DA
Hepatology; 2019 Mar; 69(3):1180-1192. PubMed ID: 30168613
[TBL] [Abstract][Full Text] [Related]
10. Plasma Methylated DNA Markers for Melanoma Surveillance.
Berger CK; Taylor WR; Mahoney DW; Burger KN; Doering KA; Gonser AM; Cao X; Heilberger J; Gysbers BJ; Foote PH; Kottschade LA; Markovic SN; Lehman JS; Katerov VE; Allawi HT; Kisiel JB; Meves A
JCO Precis Oncol; 2023 Sep; 7():e2300389. PubMed ID: 37883729
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia.
Pedersen SK; Symonds EL; Baker RT; Murray DH; McEvoy A; Van Doorn SC; Mundt MW; Cole SR; Gopalsamy G; Mangira D; LaPointe LC; Dekker E; Young GP
BMC Cancer; 2015 Oct; 15():654. PubMed ID: 26445409
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer.
Roperch JP; Incitti R; Forbin S; Bard F; Mansour H; Mesli F; Baumgaertner I; Brunetti F; Sobhani I
BMC Cancer; 2013 Dec; 13():566. PubMed ID: 24289328
[TBL] [Abstract][Full Text] [Related]
13. Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction.
Chang SC; Liew PL; Ansar M; Lin SY; Wang SC; Hung CS; Chen JY; Jain S; Lin RK
Clin Epigenetics; 2020 May; 12(1):67. PubMed ID: 32398064
[TBL] [Abstract][Full Text] [Related]
14. Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and validation study.
Jensen SØ; Øgaard N; Ørntoft MW; Rasmussen MH; Bramsen JB; Kristensen H; Mouritzen P; Madsen MR; Madsen AH; Sunesen KG; Iversen LH; Laurberg S; Christensen IJ; Nielsen HJ; Andersen CL
Clin Epigenetics; 2019 Nov; 11(1):158. PubMed ID: 31727158
[TBL] [Abstract][Full Text] [Related]
15. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
[TBL] [Abstract][Full Text] [Related]
16. The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers.
Vedeld HM; Andresen K; Eilertsen IA; Nesbakken A; Seruca R; Gladhaug IP; Thiis-Evensen E; Rognum TO; Boberg KM; Lind GE
Int J Cancer; 2015 Feb; 136(4):844-53. PubMed ID: 24948044
[TBL] [Abstract][Full Text] [Related]
17. Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer.
Yuan Z; Baker K; Redman MW; Wang L; Adams SV; Yu M; Dickinson B; Makar K; Ulrich N; Böhm J; Wurscher M; Westerhoff M; Medwell S; Moonka R; Sinanan M; Fichera A; Vickers K; Grady WM
Br J Cancer; 2017 Oct; 117(8):1202-1210. PubMed ID: 28809863
[TBL] [Abstract][Full Text] [Related]
18. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
[TBL] [Abstract][Full Text] [Related]
19. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer.
Yuan D; Li K; Zhu K; Yan R; Dang C
Cancer Biol Ther; 2015; 16(2):268-75. PubMed ID: 25629978
[TBL] [Abstract][Full Text] [Related]
20. Methylated Septin 9 as a Promising Biomarker in the Diagnosis and Recurrence Monitoring of Colorectal Cancer.
Lu P; Zhu X; Song Y; Luo Y; Lin J; Zhang J; Cao Y; Huang Z
Dis Markers; 2022; 2022():7087885. PubMed ID: 35818587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
